Yan Audrey, Hasan Nasiq, Chhablani Jay
Department of Medicine, West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA.
Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburg, PA, USA.
Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S55-S65. doi: 10.4103/IJO.IJO_1120_24. Epub 2024 Oct 25.
The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. Breakthrough drugs such as pegcetacoplan and avacincaptad have been FDA-approved for dry AMD, marking a significant development as there were no treatment options until August 2023. While several antivascular endothelial growth factor (VEGF) inhibitors have been approved for wet AMD, challenges persist with the need for frequent dosing. New treatments such as gene therapy, cell therapy, WNT pathway agonists, complement inhibitors, and anti-VEGF combination drugs are under development to address these issues. These developments are exciting and hold promise for transforming the field of medicine, offering hope for improved outcomes and enhanced patient care in managing AMD.
年龄相关性黄斑变性（AMD）领域在治疗选择方面正取得令人鼓舞的进展。诸如培西加可普朗和阿伐西普他等突破性药物已获美国食品药品监督管理局（FDA）批准用于治疗干性AMD，这是一项重大进展，因为在2023年8月之前尚无治疗选择。虽然几种抗血管内皮生长因子（VEGF）抑制剂已被批准用于湿性AMD，但由于需要频繁给药，挑战依然存在。基因治疗、细胞治疗、WNT通路激动剂、补体抑制剂和抗VEGF联合药物等新疗法正在研发中，以解决这些问题。这些进展令人兴奋，有望变革医学领域，为改善AMD治疗效果和加强患者护理带来希望。
